Frank M. Horling

R&D Baxalta Innovations GmbH
Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

Journal: mAbs

Published: April 04, 2025

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

Journal: Blood advances

Published: September 29, 2023

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.

Journal: Frontiers in immunology

Published: March 14, 2022

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 21, 2019

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.

Journal: Human gene therapy methods

Published: February 09, 2019

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.

Journal: Molecular therapy. Methods & clinical development

Published: January 29, 2019

Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.

Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 25, 2018

A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?

A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?

Journal: Journal of pharmaceutical and biomedical analysis

Published: February 19, 2016

Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.

Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 23, 2015

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Journal: Pharmaceutical research

Published: December 04, 2015

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: July 03, 2015

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Journal: Expert review of clinical pharmacology

Published: February 10, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026